A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Several mutations in Rho proteins have been identified in large scale sequencing of cancers. These mutations are listed in the Catalogue of Somatic Mutations database (http://www.sanger.ac.uk/genetics/CGP/cosmic/). The functional consequences of these mutations are unknown.
=== Early works and origins === The Fisher King first appears in Chrétien de Troyes's Perceval, the Story of the Grail in the late 12th century, but the character's roots may lie in Welsh mythology. He may be derived from the figure of Brân the Blessed in the Mabinogion. In the Second Branch of the Mabinogi, Bran has a cauldron that can resurrect the dead, albeit imperfectly: the revived dead can no longer speak. He gives this cauldron to the king of Ireland as a wedding gift for him and Bran's sister Branwen. Later, Bran wages war on the Irish and is wounded in the foot or leg, and the cauldron is destroyed. He asks his followers to sever his head and take it back to Britain, and his head continues talking and keeps them company on their trip. The group lands on the island of Gwales, where they spend 80 years in a castle of joy and abundance, but eventually they leave and bury Bran's head in London. This story has analogues in two other important Welsh texts: the Mabinogion tale "Culhwch and Olwen", in which King Arthur's men must travel to Ireland to retrieve a magical cauldron, and the poem The Spoils of Annwn, which speaks of a similar mystical cauldron sought by Arthur in the otherworldly land of Annwn.
16 February – The RMT announce four new days of train strikes for 16, 18 and 30 March, and 1 April. 17 February David Ballantyne Smith, a former security guard at the British embassy in Berlin who attempted to sell confidential information to the Russians, is sentenced to 13 years imprisonment following a trial at the Old Bailey. Storm Otto strikes Scotland and parts of northern England, leaving around 30,000 homes without power and forcing a number of schools to close. COVID-19 in the UK: Office for National Statistics data for the week up to 7 February indicates that COVID-19 cases continued to increase in England, Wales and Scotland, but decreased in Northern Ireland. In England, In England it is estimated that 1,054,200 people had COVID-19, equating to 1.88% of the population, or around 1 in 55 people. 18 February – Coronation of Charles III and Camilla: Twelve new pieces of music are commissioned by the King for his coronation, including a composition by Andrew Lloyd Webber. Part of the service will also be in Welsh, it is confirmed. 19 February – Police searching for Nicola Bulley, missing since 27 January, announce they have found a body in the River Wyre. 20 February Lancashire Police confirm the body found in the River Wyre the previous day is that of Nicola Bulley. Prime Minister Rishi Sunak criticises the rewriting of Roald Dahl's books after they were updated to remove references that could be considered offensive, such as characters being fat.
=== Detectors === The detectors used in surface plasmon resonance convert the photons of light reflected off the metallic film into an electrical signal. A position sensing detector (PSD) or charged-coupled device (CCD) may be used to operate as detectors.
Parsons was declared dead on arrival at Yucca Valley Hospital at 12:15 a.m. on September 19, 1973. The official cause of death was an overdose of morphine and alcohol. Kaufman drove Fisher and McElroy back to Los Angeles and then dispersed the rest of Parsons' drugs in the desert.
Sources: en.wikipedia.org
==== Liver ==== Liver problems in people with rheumatoid arthritis may be from the underlying disease process or the medications used to treat the disease. A coexisting autoimmune liver disease, such as primary biliary cirrhosis or autoimmune hepatitis may also cause problems.
== Treatment == PKU is not curable. However, if it is diagnosed early enough, an affected newborn can grow up with normal brain development by managing and controlling phenylalanine ("Phe") levels through diet, or a combination of diet and medication. If dietary treatment is not initiated within 2 weeks after birth, the child is likely to develop permanent intellectual disability, even if dietary interventions begin shortly thereafter.
All of these effects scale with pennation angle; greater angles lead to greater force due to increased fiber packing and PCSA, but with greater losses in shortening speed and excursion. Types of pennate muscle are unipennate, bipennate, and multipennate. A unipennate muscle has similarly angled fibers that are on one side of a tendon. A bipennate muscle has fibers on two sides of a tendon. Multipennate muscles have fibers that are oriented at multiple angles along the force-generating axis, and this is the most general and common architecture.
== Types == There are mainly two types of granules based on the presence or absence of a membrane: membrane-bound granules, and non-membrane-bound granules. Eosinophilic granules, basophilic granules, and secretory granules are examples of membrane-bound granules, while P-granules and stress granules are examples of non-membrane-bound granules.
Sources: en.wikipedia.org
==== Considerations of disease causes ==== Although TCM and its concept of disease do not strongly differentiate between cause and effect, pattern discrimination can include considerations regarding the disease cause; this is called 病因辩证 (bìngyīn biàn zhèng, "disease-cause pattern discrimination"). There are three fundamental categories of disease causes (三因; sān yīn) recognized:
Byzantine music is eclectically descended from early Christian plainsong, Jewish music, and a variety of ancient music; its exact connections to ancient Greek music remain uncertain. It included both sacred and secular traditions, but the latter is little known, whereas the former remains the central music of Eastern Orthodox liturgy into the 21st century. The empire's church music, known as Byzantine chant, was exclusively unaccompanied monodic vocal music, sung in Greek. From the 8th century, chant melodies were governed by the Oktōēchos framework, a set of eight modes—echos (ἦχος; lit. 'sound')—which each provide predetermined motivic formulae for composition. These formulae were chosen for proper text stress and occasionally for text painting, then collated through centonisation into hymns or psalms. Byzantine chant was central to the Byzantine Rite; the earliest music was not notated, including early monostrophic short hymns like the troparion. Proto-Ekphonetic notation (9th century onwards) marked simple recitation patterns. The neumatic Palaeo-Byzantine notation system emerged in the 10th century, and the Middle Byzantine "Round Notation" from the mid-12th century onwards is the first fully diastematic scheme. Several major forms developed alongside well-known composers: the long kontakion (5th century onwards), popularised by Romanos the Melodist; the also-extensive kanōn (late 7th century onwards), developed by Andrew of Crete; and the shorter sticheron (at least 8th century onwards), championed by Kassia.
=== Langerhans cell histiocytosis === The presence of multiple histiocytomas is now a well recognized syndrome. However, there is yet another presentation in which widespread cutaneous lesions histologically identical to histiocytoma are observed. Clinically, the lesions are almost confluent in affected regions. Rapid internal spread is observed and the affected animals have all been euthanized. There is one published account of such a case, and we have data on 3 dogs with what appears to be an identical syndrome.
The original synthesis as patented in 1964 by Paul Janssen involves the synthesis of benzylfentanyl from N-benzyl-4-piperodone. The resulting benzylfentanyl is used as feedstock to norfentanyl. It is norfentanyl that forms fentanyl upon reaction with a phenethyl halide.
In 2015, the Wildcats played in their fourth consecutive bowl game, defeating the University of New Mexico in the New Mexico Bowl. In 2017, they lost to the Purdue Boilermakers in the Foster Farms Bowl, the Wildcats 21st bowl game. Dave Heeke was named Arizona's 13th Director of Athletics in February 2017 and officially started in that role on April 1, 2017. Heeke served as Athletics Director at Central Michigan University for 11 years and as a staff member in the University of Oregon athletics department for 18 years. (Greg Byrne resigned from the post in January to accept the same role at the University of Alabama.) Rodriguez was relieved of his duties on January 2, 2018, in the wake of an internal university investigation of sexual harassment claims made by Rodriguez's former administrative assistant. After a nationwide search and much media speculation, Kevin Sumlin was hired on January 14, 2018, as the new Wildcats head football coach. Sumlin was head coach at Texas A&M University and the University of Houston. After a disappointing three-season tenure, with the Wildcats posting a 5–7 (4–5 in Pac-12) record in 2018 and a 4–8 record (2–7 in Pac-12) record in 2019, Sumlin was fired at the conclusion of the 2020 season (a truncated schedule due to the COVID-19 pandemic). After a nationwide search and much media speculation, former college and NFL coach Jedd Fisch (most recently the QB coach for the New England Patriots and a previous assistant at UCLA, Michigan, Miami and Minnesota) was chosen as the Wildcats' 32nd head football coach, as announced in December 2020.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.